科研成果详情

题名ATP citrate lyase promotes the progression of hepatocellular carcinoma by activating the REGγ-proteasome pathway
作者
发表日期2024-06-18
发表期刊Molecular Carcinogenesis   影响因子和分区
语种英语
原始文献类型Article ; Early Access
关键词ATP citrate lyase hepatocellular carcinoma proteasome pathway REG gamma
其他关键词CELL-CYCLE ; CANCER ; EXPRESSION ; PROLIFERATION ; INHIBITION ; DIAGNOSIS ; TARGET ; GROWTH
摘要The search for novel tumor biomarkers and targets is of significant importance for the early clinical diagnosis and treatment of Hepatocellular Carcinoma (HCC). The mechanisms by which ATP citrate lyase (ACLY) promotes HCC progression remain unclear, and the connection between ACLY and REG gamma has not been reported in the literature. In vitro, we will perform overexpression/knockdown of ACLY or overexpression/knockdown of REG gamma to investigate the impact of ACLY on HCC cells and its underlying mechanisms. In vivo, we will establish mouse tumor models with overexpression/knockdown of ACLY or overexpression/knockdown of REG gamma to study the effect of ACLY on mouse tumors and its mechanisms. Firstly, ACLY overexpression upregulated REG gamma expression and activated the REG gamma-proteasome pathway, leading to changes in the expression of downstream signaling pathway proteins. This promoted HCC cell proliferation, invasion, and migration in vitro, as well as tumor growth and metastasis in vivo. Secondly, ACLY overexpression increased acetyl-CoA production, upregulated the acetylation level of the REG gamma promoter region histone H3K27ac, and subsequently induced REG gamma expression. Lastly, enhanced acetylation of the REG gamma promoter region histone H3K27ac resulted in upregulated REG gamma expression, activation of the REG gamma-proteasome pathway, changes in downstream signaling pathway protein expression, and promotion of HCC cell proliferation, invasion, and migration in vitro, as well as tumor growth and metastasis in vivo. Conversely, REG gamma knockdown reversed these effects. ACLY and REG gamma may serve as potential biomarkers and clinical therapeutic targets for HCC.
资助项目Wenzhou Science and Technology Project; Province Key Surgery Projects [Zhejiang High-Tech 2008-255, Zhejiang High-Tech 2012-80, 2016-169]; [Y20210172]
出版者WILEY
ISSN0899-1987
EISSN1098-2744
卷号63期号:10页码:1874-1891
DOI10.1002/mc.23777
页数18
WOS类目Biochemistry & Molecular Biology ; Oncology
WOS研究方向Biochemistry & Molecular Biology ; Oncology
WOS记录号WOS:001248787300001
收录类别SCIE ; SCOPUS ; PUBMED
URL查看原文
PubMed ID38888205
SCOPUSEID2-s2.0-85196199495
通讯作者地址[Zhang, Qiyu;Zhu, Qiandong]Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanbaixiang St, Wenzhou 325000, Zhejiang, Peoples R China.
Scopus学科分类Molecular Biology;Cancer Research
SCOPUS_IDSCOPUS_ID:85196199495
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/215311
专题附属第一医院
附属第一医院_肝胆外科
附属第一医院_护理部
通讯作者Zhang, Qiyu; Zhu, Qiandong
作者单位
1.Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanbaixiang St, Wenzhou 325000, Zhejiang, Peoples R China;
2.Wenzhou Med Univ, Affiliated Hosp 1, Dept Nursing, Wenzhou, Peoples R China
第一作者单位附属第一医院;  肝胆外科
通讯作者单位附属第一医院;  肝胆外科
第一作者的第一单位附属第一医院
推荐引用方式
GB/T 7714
Cai, Qihong,Zhu, Honghua,Dai, Yile,et al. ATP citrate lyase promotes the progression of hepatocellular carcinoma by activating the REGγ-proteasome pathway[J]. Molecular Carcinogenesis,2024,63(10):1874-1891.
APA Cai, Qihong, Zhu, Honghua, Dai, Yile, Zhou, Qingqing, Zhang, Qiyu, & Zhu, Qiandong. (2024). ATP citrate lyase promotes the progression of hepatocellular carcinoma by activating the REGγ-proteasome pathway. Molecular Carcinogenesis, 63(10), 1874-1891.
MLA Cai, Qihong,et al."ATP citrate lyase promotes the progression of hepatocellular carcinoma by activating the REGγ-proteasome pathway".Molecular Carcinogenesis 63.10(2024):1874-1891.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Cai, Qihong]的文章
[Zhu, Honghua]的文章
[Dai, Yile]的文章
百度学术
百度学术中相似的文章
[Cai, Qihong]的文章
[Zhu, Honghua]的文章
[Dai, Yile]的文章
必应学术
必应学术中相似的文章
[Cai, Qihong]的文章
[Zhu, Honghua]的文章
[Dai, Yile]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。